Company intelligence / Profile preview

Avantogen Limited

Ownership: Private
Development stage: Phase 1

Overview

Prior to its merger with Hawaii Biotech in May/June of 2006, Avantogen was developing a broad portfolio of oncology drugs and had advanced a vaccine adjuvant program into Phase I human trials and the Pentrys vaccine program into Phase II human trials. Post-merger activities continued under the Hawaii Biotech name.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesVaccines/adjuvants
Industry: Biotech

Drug pipeline

1 asset

GPI-0100

Unknown

Partnerships

Merged/commercial partnership with Hawaii Biotech Inc.Received significant funding from NIH and other government agencies for infectious disease vaccines.

Beyond the preview

Go deeper on Avantogen Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avantogen Limited.

Explore the full profile